Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
Open accessPublished version of a preprint
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 15 of the 29 sources its claims cite were checked for support.
Abstract
SagA promotes immunotherapy response: The gut microbiome can influence the treatment outcome for cancer patients receiving PD-L1 immunotherapy, but the mechanisms underlying favorable responses are unclear. Griffin et al . found that a particular type of bacteria called enterococci enhance anti–PD-L1 immunotherapy in mice (see the Perspective by Ansaldo and Belkaid). The researchers show that enterococci secrete an enzyme called SagA that breaks down components of the bacterial cell wall. This process results in the release of muramyl peptide fragments, which in turn act as stimulatory molecules to promote signaling of the innate immune sensor protein NOD2 and improved immunotherapy responses. —PNK
Overview
CoChat Summary
TL;DR
Enterococcus species that produce secreted NlpC/p60 peptidoglycan hydrolases (SagA orthologs) improve checkpoint inhibitor responses in mouse tumor models by generating NOD2-active muropeptides. Engineering SagA into non-active E. faecalis or probiotic L. lactis, or giving synthetic MDP-l,d, reproduced antitumor benefit with anti-PD-L1.
Key findings
- In antibiotic-pretreated C57BL/6 mice bearing B16-F10 melanoma, oral E. faecium Com15 plus anti-PD-L1 reduced tumor size at high and low antibody doses versus anti-PD-L1 alone; all three E. faecium isolates tested were active, while no E. faecalis strain was. Similar fecal CFU across strains indicated the effect was not due to bacterial load.
- Active species E. durans, E. hirae, and E. mundtii shared peptidoglycan remodeling signatures and SagA orthologs; C-terminal NlpC/p60 domains were >90% identical, E. gallinarum’s closest protein was 67% identical, and E. faecalis lacked direct orthologs. Recombinant orthologs showed d,l-endopeptidase activity producing GMDP.
- E. faecalis engineered to express SagA plus anti-PD-L1 reduced B16-F10 growth, and this required NOD2. L. lactis expressing wild-type SagA matched E. faecium benefit, whereas catalytically inactive C443A SagA did not.
- Synthetic NOD2-active MDP-l,d with anti-PD-L1 significantly inhibited tumors, unlike MDP-l,l; scRNA-seq showed more intratumoral T lymphocytes, cytotoxic gene enrichment, a Cx3cr1/Nr4a1 monocyte increase, and NF-κB/inflammatory signatures.
Methods
- Mouse tumor models: SPF C57BL/6 mice (Jackson) pretreated two weeks with ampicillin, colistin, and streptomycin, then orally supplemented with enterococci, implanted with B16-F10 melanoma and treated with anti-PD-L1; separate Taconic SPF mice without antibiotics; MCA205 fibrosarcoma with anti-PD-1 and MC38 colorectal carcinoma with anti-CTLA-4; B16-OVA for flow cytometry.
- Bacterial and biochemical assays: HPLC-MS peptidoglycan fragment profiling, genomic/sequence alignments for SagA orthologs, Western blot for secretion, recombinant hydrolase activity assays, fecal/tissue CFU, and 16S rRNA microbiome analysis.
- Immune profiling: tumor-infiltrating lymphocytes quantified by flow cytometry; CD45+ tumor cells from MDP stereoisomer-treated mice analyzed by scRNA-seq and gene set enrichment.
Limitations
- Stated: the authors could not detect SagA orthologs in clinical metagenomic datasets before checkpoint blockade, which they attribute to low E. faecium genome coverage (9.34%). They also note uncertainty for the secretion-deficient L. lactis SagA strain, suggesting either low secreted SagA was sufficient or non-secreted SagA leaked via lysis.
- Evident: efficacy and mechanism data come from mouse tumor models and bacterial/muropeptide interventions, not human clinical trials; antibiotic pretreatment substantially depletes resident microbiota, although a non-antibiotic SPF model was also used.
- Evident: microbiome analyses showed incomplete antibiotic clearance and shifts over time, and some differential OTUs appeared in only one cage per condition, limiting microbiome attribution.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 7 Not checked · 63 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple analyses of the commensal microbiome from human cohorts treated with immunotherapies targeting PD-1 have revealed that the bacterial genus Enterococcus is enriched in responding patients (12, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the paper’s results (our copy labels the section Abstract; page unavailable), Enterococcus faecium is listed among species more abundant in responders. The paper reports enrichment of that species in a metastatic melanoma cohort, not enrichment of the genus Enterococcus as a whole across human cohorts. (LLM, conf=0.83)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, the gut microbiota has emerged as a potent new factor associated with the efficacy of anti–CTLA4, anti–PD-1, and anti–PD-L1 treatment (8-14).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Partly supportedcites [8] Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther P-L, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350, 1079– 1084 (2015). 26541610 PMC4721659 sourceExperimental — accuracy not yet measured
The Abstract reports that gut microbiota composition influences the efficacy of CTLA-4 blockade, supporting the anti-CTLA-4 part of the sentence. The passages in our copy do not establish the same association for anti-PD-1 or anti-PD-L1 treatment, so this source does not support the full three-treatment claim. (LLM, conf=0.88)
- Partly supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 sourceExperimental — accuracy not yet measured
The supplied passages report that gut microbial composition influenced response to anti–PD-L1 treatment in mice. They discuss effects on the PD-1/PD-L1 axis more broadly, but do not report a direct anti–PD-1 treatment test; the CTLA-4 passage says the principles *could* apply to that pathway. Thus this source supports the anti–PD-L1 part, but not the claim that microbiota is established as associated with efficacy for all three treatments. (LLM, conf=0.88)
- Supportedcites [10] Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY, Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 19, 848– 855 (2017). 28923537 PMC5602478 source
The Introduction reports that gut microbiota influence responses to anti-PD-L1 and anti-CTLA4 therapy in mouse models. The Discussion reports gut microbial species associated with clinical response to anti-PD1 alone and combined anti-PD1/anti-CTLA4 therapy in melanoma patients. Together, these passages support the broad association claimed; page numbers are not provided in our copy. (LLM, conf=0.92)
- Supportedcites [11] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza I source
The paper reports an association between gut microbiome composition and anti-PD-1 response in melanoma patients, cites a similar finding in a small anti-CTLA-4 cohort, and reports improved anti-PD-L1 response in mice receiving fecal transplants from anti-PD-1 responders. These passages support the broad association claimed, although the evidence comes from different populations and study designs. (LLM, conf=0.87)
- Not checked yetcites [12] Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria J-C, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L, Gut microbiome influences efficacy of PD-1–ba source
- Partly supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
The paper reports an association between gut microbiota and anti–PD-1 response in metastatic melanoma patients, and its mouse experiments show differing anti–PD-L1 efficacy by microbiota (Abstract; Fig. 3F discussion; page unavailable). It included four anti–CTLA-4 recipients but reports no separate microbiota–efficacy association for that treatment. The anti–PD-L1 result is in mice, not patients. (LLM, conf=0.88)
- Supportedcites [14] Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J, Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019). 31597568 PMC6785875 source
The Background reports gut-microbiota effects on anti-CTLA-4 and anti-PD-L1 immunotherapy in mice and an association with clinical response in human melanoma patients. The Discussion describes associations with response to anti-PD-1 and anti-CTLA-4 treatment in melanoma patients. Together, these passages support the broad association attributed to this source. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“consistent with enhanced priming of a tumor antigen-specific immune response (9, 13).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [9] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre M-L, Chang EB, Gajewski TF, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350, 1084– 1089 (2015). 26541606 PMC4873287 source
The paper reports greater expansion of tumor-antigen-specific CD8+ T cells in tumor-draining lymph nodes and describes differences in T-cell priming in vivo (passages [1] and [2], page unavailable). This supports the cited interpretation that an increase in antigen-specific CD8+ T cells is consistent with enhanced priming. The paper studied SIY-specific cells; the citing paper’s OVA-specific observation is not itself attributed to this source. (LLM, conf=0.88)
- Supportedcites [13] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 359, 104– 108 (2018). 29302014 PMC6707353 source
The passage describing the mouse tumor experiment reports more SIY-specific CD8+ T cells and explicitly interprets this as increased priming of tumor antigen-specific CD8+ T cells. The citation is attached to that interpretation, not to the citing study’s OVA-specific measurement. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Significant enrichment of hallmark gene sets (33) for inflammatory response and NF-κB signaling were found in the MDP-l,d dataset (Table S8).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [33] Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P, The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417– 425 (2015). 26771021 PMC4707969 source
The citation (33) is attached to 'hallmark gene sets' — an identification of the resource the citing authors ran enrichment against — not to their own MDP-l,d result. Our copy is exactly that source: the DISCUSSION states the hallmarks are released as the H Collection in MSigDB v5.0, every set name starting with HALLMARK, with Table 1 listing all 50 hallmarks and their descriptions; the RESULTS (Analysis of necrosis in glioblastoma) treat NFκB signaling as one of the biological themes covered, and the protein-phenotype validation section documents the immune/inflammatory hallmarks (IL6 JAK STAT3, IL2 STAT5 signaling). No passage of our copy reports anything about an 'MDP-l,d' dataset, which is consistent with that being the citing authors' own analysis rather than something attributed here. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We further confirmed that SagA orthologs are found in humans through alignment of the SagA NlpC/p60 domain with genomes within the Human Microbiome Project (24) (Fig. 2C, Table S5).”
§ Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor immunotherapy > Abstract
What the sources say
- Supportedcites [24] Consortium THMJRS, A catalog of reference genomes from the human microbiome. Science. 328, 994– 999 (2010). 20489017 PMC2940224 source
The citation identifies the Human Microbiome Project genomes used for the citing authors’ alignment; the SagA result is presented as the citing authors’ own finding. The source’s Reference genome progress section describes the HMP-sequenced genomes, and its Data release section says their sequences and annotations were made available. (LLM, conf=0.91)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims
Create a free account to see all 78 claims and to verify the 14 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, cause-effect relationships between the prevalence or relative abundance of particular taxa, and clinical regression or progression, have been shown in animal models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several probiotics or their products can inhibit tumor development by suppressing inflammation and promoting anti-tumor immune responses6,7.”
From Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Enterococcus expressed and secreted orthologs NlpC/p60 PG hydrolase SagA and could promote expression of the innate immune sensor protein nucleotide-binding oligomerization domain containing 2 (NOD2) and augment ICI antitumor efficacy [109] (Fig. 5F).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [109]
In the citing paper
“Thus, the peptidoglycan hydrolase SagA from Enterococcus faecium can be transferred into Lactococcus lactis to generate a probiotic strain that stimulates innate immune responses via NOD2 activation and promotes ICI antitumor activity in mice.26”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [26]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies
Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., & Minh, B. Q. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msu300 · Cited by 26,046
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
FastTree 2 – Approximately Maximum-Likelihood Trees for Large Alignments
Price, M. N., Dehal, P. S., & Arkin, A. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009490 · Cited by 14,894
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Cited by
Items 101–200 of 367
The Diagnostic Potential of the Human Blood Microbiome: Are We Dreaming or Awake?
Sciarra, F., Franceschini, E., Campolo, F., & Venneri, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310422 · Cited by 40
Microbiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
“Similarly, the peptidoglycan hydrolase SagA produced by Enterococcus faecalis generates specific immunoactive muropeptides that activate the peptidoglycan sensor NOD2 and enhance response to immunotherapy (Griffin et al. 2021).”
BackgroundYu, H., Lin, G., Jiang, J., Yao, J., Pan, Z., Xie, H., Bo, Z., He, Q., Yang, J.-H., Chen, Z., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2410474 · Cited by 35
Intratumoral microbiota: new frontiers in tumor immunity
Zhang, Z., Liao, Y., & Tang, D. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac063 · Cited by 32
Zhao, R., Hou, Y., Li, B., Pan, Z., Qiu, J., Wang, Q., Qi, Y., Han, Z. W., Zhao, H., Liu, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63081-2 · Cited by 49
Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 34
“Further, Grif fi n et al. determined that Enterococcus spp. with unique NlpC/p60 peptidoglycan hydrolase activity may produce NOD2-active muropeptides; these muropeptides could then alter the effectiveness of checkpoint blockade immunotherapy in vivo (30).”
BackgroundApostolos, A. J., Chordia, M. D., Kolli, S. H., Dalesandro, B. E., Rutkowski, M. R., & Pires, M. M. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.11.010 · Cited by 30
Convergence of Nanotechnology and Bacteriotherapy for Biomedical Applications
Liu, J., Yuan, S., Bremmer, A., & Hu, Q. (2024) · Advanced Science · doi:10.1002/advs.202309295 · Cited by 31
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Microbial mechanisms to improve immune checkpoint blockade responsiveness
Griffin, M. E., & Hang, H. C. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100818 · Cited by 31
Self-citationKwan, J. M. C., Liang, Y., Ng, E. W. L., Sviriaeva, E. N., Li, C., Zhao, Y., Zhang, X.-L., Liu, X., Wong, S. H., & Qiao, Y. (2024) · Chemical Science · doi:10.1039/d3sc05819k · Cited by 27
Li, J., Li, S., Sun, Q., Li, L., Zhang, Y., & Hua, Z. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03399-2 · Cited by 30
Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy
Bae, J., Park, K., & Kim, Y. (2022) · Immune Network · doi:10.4110/in.2022.22.e3 · Cited by 32
“faecium alone did not exhibit a significant tumor inhibitory effect (81).”
BackgroundFeng, X., Li, Z., Guo, W., & Hu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1087755 · Cited by 28
“Similarly, SagA, an enzyme expressed by Enterococcus faecium, enhances the effect of immunotherapy in HCC (69).”
BackgroundInfluentialYu, S., Ge, X., Xu, H., Tan, B., Tian, B., Shi, Y., Dai, Y., Li, Y., Hu, S., & Qian, J. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1129043 · Cited by 30
Small molecule modulators of immune pattern recognition receptors
Tsukidate, T., Hespen, C. W., & Hang, H. C. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00096f · Cited by 28
Self-citationSaid, S., & Ibrahim, W. (2025) · Cancer Management and Research · doi:10.2147/cmar.s405590 · Cited by 25
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 33
“Enterococcus peptidoglycan (64) and Enterococcus bacteriophage (65) can also improve curative effect of CI.”
BackgroundResultWang, S., Xu, B., Zhang, Y., Chen, G., Zhao, P., Gao, Q., & Yuan, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0376 · Cited by 32
“Investigators produced SagA-engineered probiotics and found that SagA-engineered probiotics enhance anti-tumor efficacy of anti-PD-L1 antibody therapy 114 .”
MethodRecT Recombinase Expression Enables Efficient Gene Editing in Enterococcus spp.
Chen, V., Griffin, M. E., Maguin, P., Varble, A., & Hang, H. C. (2021) · Applied and Environmental Microbiology · doi:10.1128/aem.00844-21 · Cited by 27
Self-citationPrecision Probiotic Medicine to Improve ICB Immunotherapy
Luccia, B. D., & Colonna, M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0221 · Cited by 24
Gut microbiota and immune alteration in cancer development: implication for immunotherapy
Lau, H. C.-H., Zhang, X., & Yu, J. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100007 · Cited by 25
The microbiome, gastrointestinal cancer, and immunotherapy
Newsome, R. C., Yang, Y., & Jobin, C. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15742 · Cited by 28
Park, J. S., Gazzaniga, F. S., Kasper, D. L., & Sharpe, A. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01075-0 · Cited by 25
“For example, stimulation of NOD2 with muramyl dipeptide induces PD-L1 and ICOSL on human monocytes 105,106 .”
InfluentialSun, Y., Gan, Z., Wang, X., Liu, J., Wei, Z., Zhang, Z., Zuo, J., Zhong, H., Huang, X., Yan, Z., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05485-0 · Cited by 28
“E. faecium has garnered significant attention in tumor immunotherapy recently due to its ability to enhance T-cell responses and improve the efficacy of anti-PD-L1 antitumor treatments [49, 50].”
Potential of natural products and gut microbiome in tumor immunotherapy
Cao, L., Wang, X., Ma, X., Xu, M., & Li, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01032-7 · Cited by 25
Lim, M. Y., Hong, S., & Nam, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512683 · Cited by 27
García-Vello, P., Tytgat, H. L. P., Gray, J., Elzinga, J., Lorenzo, F. D., Biboy, J., Vollmer, D., Castro, C. D., Vollmer, W., de Vos, W. M., et al. (2022) · Glycobiology · doi:10.1093/glycob/cwac027 · Cited by 24
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
Wang, W., Fan, J., Zhang, C., Huang, Y., Chen, Y., Fu, S., & Wu, J. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127668 · Cited by 25
Emerging chemophysiological diversity of gut microbiota metabolites
Lin, X., He, K., Gu, Z., & Zhao, X. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.07.006 · Cited by 25
Microrobotic Swarms for Cancer Therapy
Xie, L., Liu, J., Yang, Z., Chen, H., Wang, Y., Du, X., Fu, Y., Song, P., & Yu, J. (2025) · Research · doi:10.34133/research.0686 · Cited by 30
“Bacteria possess inherent tumor-targeting capabilities, and their surface components or metabolic byproducts can stimulate the immune system, inducing antitumor responses [ 137 ], such as peptidoglycan and lipopolysaccharide (LPS) [ 138 , 139 ].”
Wekking, D., Silva, C. A. C., Viscò, R., Denaro, N., Lambertini, M., Maccioni, A., Loddo, E., Willard-Gallo, K. E., Scartozzi, M., Derosa, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104767 · Cited by 30
Liu, Q., Wu, Y., Fan, Q., Liu, J., Chen, Y., He, Y., Wei, W., Zhang, H., Zhao, Y., He, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c01158 · Cited by 24
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 24
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
“Likewise, any bacterial peptidoglycan-derived muropeptides that stimulate NOD2 are expected to expand cytotoxic CD8⁺ T cell populations 92 .”
Xia, C., Cai, Y., Ren, S., & Xia, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051330 · Cited by 22
Xie, Y., Wang, L., Yang, Y., Zha, L., Zhang, J., Rong, K., Tang, W., & Zhang, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1071255 · Cited by 23
“Hydrolases and synthases can modulate invasion of prey cells, cell shape, innate immune detection, and intercellular communication, and inhibit or stop bacterial growth and daughter cell separation at very low level (Rangan et al., 2016; Griffin et al., 2021).”
BackgroundZhang, F., Jiang, Q., Cai, J., Meng, F., Tang, W., Liu, Z., Lin, X., Liu, W., Zhou, Y., Shen, X., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp8266 · Cited by 31
“Of note, Griffin et al. highlighted that Enterococcus can produce NOD2-active muropeptides, thereby enhancing the anti– PD-L1 antitumor efficacy in melanoma, indicating the potential of NLRs in advancing tumor immunotherapy ( 16 ).”
Bacteria-driven bio-therapy: From fundamental studies to clinical trials
Yu, Y., Lin, S., Chen, Z., Qin, B. Y., He, Z., Cheng, M., Sun, M., & Sun, J. Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101731 · Cited by 26
Kwan, J. M. C., & Qiao, Y. (2023) · ChemBioChem · doi:10.1002/cbic.202200693 · Cited by 22
Čierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 24
“In an animal study, oral supplementation with Enterococcus faecium and Enterococcus faecalis before melanoma cell injection and anti-PD-L1 treatment led to a significantly reduced tumor size in experimental mice compared to those treated with anti-PD-L1 alone [93].”
Recent advances of engineered probiotics for therapeutic applications
Zhang, L., Chen, N., Chen, H., Tang, C., Wang, J., Wang, Y., Zhang, Y., Guo, H., & Yuan, J. (2025) · BioDesign Research · doi:10.1016/j.bidere.2025.100039 · Cited by 32
“[28] 2021 EcN Lacks the ArgR , enabling it to continuously convert the ammonia accumulated in tumors into L-arginine.”
Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome
Al-Btoosh, S., Donnelly, R. F., & KELLY, S. C. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2604867 · Cited by 28
Liu, Y., chen, J., Raj, K., Baerg, L., Nathan, N., Philpott, D. J., & Mahadevan, R. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00583 · Cited by 20
The gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 22
“Other gut microbial signatures guide antitumor immune response Griffin et al. (2021) demonstrated that the secretion of enterococcus homologous NlpC/p60 pg hydrolase SagA can promote the nucleotide-binding oligomyelization domain of innate immune sensor protein containing 2 (NOD2) and improve the…”
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
“SagA-engineered Lactobacillus lactis is also able to augment anti-PD-L1 antitumor efficacy in CRC allograft mouse model (Griffin et al., 2021).”
Lin, Y., Ding, J. L., Shen, H.-T., Lin, Y.-M., Adhidjaja, E. C., & Chang, S. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09105-7 · Cited by 25
“Hence, immune signaling and responses to cancer immunotherapy are boosted by the Enterococci [138].”
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
“60 The microbial metabolite TMAO promoted infiltration of TAMs, increased the proportion of TNF-α + IFN-γ + T cells in the tumour tissues and inhibited tumour growth.”
BackgroundInfluentialMicroecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu, X.-L., Li, S., Ma, K.-X., & Wang, L. (2024) · Biochimica et Biophysica Acta - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167230 · Cited by 20
Klupt, S., Fam, K. T., Zhang, X., Chodisetti, P. K., Mehmood, A., Boyd, T., Grotjahn, D. A., Park, D., & Hang, H. C. (2024) · eLife · doi:10.7554/elife.95297 · Cited by 23
Self-citationEnterococci—Involvement in Pathogenesis and Therapeutic Potential in Cancer Treatment: A Mini-Review
Grenda, A., Grenda, T., Domaradzki, P., & Kwiatek, K. (2022) · Pathogens · doi:10.3390/pathogens11060687 · Cited by 21
Depletion of gut microbiota improves the therapeutic efficacy of cancer nanomedicine
Prajnamitra, R. P., Cheng, Y., Beh, C. Y., Lu, C.-Y., Lin, J.-H., Ruan, S., Chen, S.-L., Chen, H.-C., Yang, R., & Hsieh, P. C. H. (2022) · Theranostics · doi:10.7150/thno.73873 · Cited by 19
Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy
Olekhnovich, E. I., Ivanov, A. B., Babkina, A. A., Sokolov, A. A., Игоревич, У. В., Fedorov, D. E., & Ilina, E. N. (2023) · mSystems · doi:10.1128/msystems.01023-22 · Cited by 21
Fecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
Huang, W., Jin, L., Yin, H., Tang, S., Yu, Y., & Yang, Y. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.164823 · Cited by 20
The effects of NOD-like receptors on adaptive immune responses
Tsankov, B. K., Luchak, A., Carr, C., & Philpott, D. J. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100637 · Cited by 19
“Recently, it has been shown that NOD2 signalling in response to the gut microbiota is an important contributor to immune checkpoint blockade therapy in mice, increasing tumor infiltrating CD8 + T cells and decreasing tumour size [50].”
BackgroundAn oral bacterial pyroptosis amplifier against malignant colon cancer
Lou, X., Wang, J., Jin, X., Wang, X., Qin, B., Liu, D., Shi, X., Ouyang, D., He, Z., Sun, J., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102091 · Cited by 18
Bo, T., Wang, C., Yao, D., Jiang, Q., Zhao, Y., Wang, F., He, W., Xu, W., Zhou, H., Li, M., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.024 · Cited by 20
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
Xiao, J., Chen, C., Fu, Z., Wang, S., & Luo, F. (2024) · Microorganisms · doi:10.3390/microorganisms12050994 · Cited by 17
“…foods but also extensively used in animal health [13], such as restoration of microbiota balance of the gastrointestinal tract (GIT) with antibiotic-induced dysbiosis [14–16], antiviral activity [17], antitumor effect [18,19], cholesterol-lowering effect [20], and immune regulation [21–23].”
BackgroundNing, W., Cheng, D., Howe, P. H., Bian, C., Kamen, D. L., Luo, Z., Fu, X., Ogunrinde, E., Yang, L., Wang, X., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102860 · Cited by 17
Mattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Luo, B., An, Q., Lei, J., Tan, D., Liu, X., Li, H., Zhao, Y., Qin, J., Zhang, C., Zhang, Y., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2447821 · Cited by 21
Chemoproteomic Analysis of Microbiota Metabolite–Protein Targets and Mechanisms
Zhao, X., Yang, X., & Hang, H. C. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00758 · Cited by 16
Self-citationQiao, S., Li, T.-T., Jeong, M., Chuanfa, L. I. U., Mizutani, S., Hwang, S.-M., Li, Y., Lyu, M., Nishiyama, K., Tang, Y.-A., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2025.12.003 · Cited by 17
Bacterial subversion of NLR-mediated immune responses
Kienes, I., Johnston, E. L., Bitto, N. J., Kaparakis‐Liaskos, M., & Kufer, T. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930882 · Cited by 16
“Interestingly, some bacteria such as commensal Enterococcus species have been shown to modify their release of PGN fragments which resulted in increased activation of murine NOD2 (27).”
BackgroundGut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer
Yuan, H., Gui, R., Wang, Z., Fang, F., & Zhao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128774 · Cited by 18
“faecalis can expresses sufficient SagA to enhance the anti-tumor effects of PD-L1 in mice (58).”
BackgroundWei, W., Gao, W., Li, Q., Liu, Y., Chen, H., Cui, Y., Sun, Z. S., & Liu, Z. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00305-0 · Cited by 16
The multi-kingdom cancer microbiome
Dohlman, A. B., Pan, X., Zitvogel, L., & Iliev, I. D. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02103-7 · Cited by 18
N-Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy
Griffin, M. E., Tsukidate, T., & Hang, H. C. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00085 · Cited by 15
Self-citationNano-armor modification of bacteria through supramolecular interactions for disease treatment
Cao, X., Wang, Y., Wang, Q., Huang, Y., Ding, Y., & Mao, Z. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216165 · Cited by 15
Wheeler, R., & Boneca, I. G. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2395099 · Cited by 18
Outgrowth of Escherichia is susceptible to aggravation of systemic lupus erythematosus
Gui, L., Zuo, X., Feng, J., Wang, M., Chen, Z., Sun, Y., Qi, J., Chen, Z., Pathak, J. L., Zhang, Y., et al. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03413-7 · Cited by 14
“As a part of the bacterial cell wall, PGN is highly antigenic due to conserved structural molecular motifs unique to a bacterium, which derived from different bacteria can uniquely modulate immune activities [52].”
BackgroundChemical genetic approaches to dissect microbiota mechanisms in health and disease
Yang, X., & Hang, H. C. (2024) · Science · doi:10.1126/science.ado8548 · Cited by 16
Self-citationEnterococcus Species: Multifaceted Probiotic Potential and Safety Considerations
John, O. P., Afolabi, K. O., Ngene, A. C., Tanimowo, W. O., Adewoyin, M. A., Osho, M. B., & Reuben, R. C. (2026) · Microorganisms · doi:10.3390/microorganisms14040815 · Cited by 14
Training the microbiota to increase immune checkpoint blockade and to reduce toxicity
Rescigno, M. (2023) · European Journal of Immunology · doi:10.1002/eji.202250183 · Cited by 16
“Some members of Enterococcus can secrete a peptidoglycan NlpC/p60 hydrolase called SagA that can produce muropeptides that can activate the immune response via NOD2 [31].”
BackgroundRashid, M., Narang, A., Thakur, S., Jain, S. K., & Kaur, S. (2023) · Gut Pathogens · doi:10.1186/s13099-023-00548-x · Cited by 14
Gong, X., Shen, L., Xie, J., Liu, D., Xie, Y., & Liu, D. (2023) · Helicobacter · doi:10.1111/hel.13011 · Cited by 13
Integrating functional metagenomics to decipher microbiome–immune interactions
Sardar, P., Almeida, A., & Pedicord, V. A. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12798 · Cited by 16
The Microbiome and Liver Cancer
Myojin, Y., & Greten, T. F. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000646 · Cited by 13
Poletto, S., Paruzzo, L., Nepote, A., Caravelli, D., Sangiolo, D., & Carnevale‐Schianca, F. (2023) · Cancers · doi:10.3390/cancers16010101 · Cited by 15
“For example, microbiota species with specialized peptidoglycan remodeling activity and muropeptide-based therapeutics were demonstrated to enhance immunotherapy [76].”
BackgroundGut microbiota affects PD-L1 therapy and its mechanism in melanoma
Liu, S., Liu, J., Mei, Y., & Zhang, W. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04018-y · Cited by 14
“It improves the tumor immune microenvironment and enhances the efficacy of multiple immunotherapeutic mAbs [83].”
Cancer trigger or remedy: two faces of the human microbiome
Grenda, A., & Krawczyk, P. A. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11125-0 · Cited by 13
Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis
Liu, Q.-L., Zhou, H., Wang, Z., & Chen, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1563184 · Cited by 14
Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy
Yan, D., Yu, Y., Liang, C., Cui, Z., Shi, L., Li, G., & Ren, C. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02566-6 · Cited by 12
“…(TNF-α, IL-6) induce soluble PD-1, interfering with the PD-1/PD-L1 signaling axis [224]; Enterococcus improves ICI response in mouse models [225]; interferons upregulate PD-L1 expression by activating the STING pathway, promoting IFN-γ + CD8 + TIL aggregation and enhancing PD-L1 blockade…”
Liu, L., Du, Y., Du, Y., Yan, W., Li, Y., Cui, K., Li, Z., Yu, P., Zhang, W., Feng, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127625 · Cited by 14
Yin, Q., Ni, J., & Ying, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1263 · Cited by 13
“111,112 In addition to PD ‐ L1, PD ‐ L2 is also an important ligand in the PD ‐ 1 signaling pathway.”
BackgroundKamiya, T., & Ohtani, N. (2022) · International Immunology · doi:10.1093/intimm/dxac020 · Cited by 12
NOD1 and NOD2 Are Potential Therapeutic Targets for Cancer Immunotherapy
Wang, D. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/2271788 · Cited by 11
RetractedFuochi, V., Spampinato, M., Distefano, A., Palmigiano, A., Garozzo, D., Zagni, C., Rescifina, A., Volti, G. L., & Furneri, P. M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1082526 · Cited by 14
“Based on this evidence, some papers suggest the importance of peptidoglycan remodeling enzymes in reprogramming probiotic bacteria to enhance the host’s immune response mechanisms (Griffin et al., 2021).”
BackgroundGRAP2 is a prognostic biomarker and correlated with immune infiltration in lung adenocarcinoma
Song, S., Deng, X., Jiang, S., Tian, C., Han, J., Chai, J., Li, N., Yan, Y., & Luo, Z. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24662 · Cited by 11
Microbial metabolites for cancer immunotherapy: Current evidence and future directions
Wang, X., Liang, J.-J., Duan, X., & Chen, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.005 · Cited by 12
Gut bacteria, host immunity, and colorectal cancer: From pathogenesis to therapy
Li, Y., Peng, J., & Meng, X. (2024) · European Journal of Immunology · doi:10.1002/eji.202451022 · Cited by 11
“These fragments further promote NOD2 signaling, thereby enhancing the efficacy of anti-CTLA-4 and anti-PD-1 immunotherapy in various malignant tumors, including CRC [105].”
When the Host Encounters the Cell Wall and Vice Versa
Kho, K., Cheng, T., Buddelmeijer, N., & Boneca, I. G. (2024) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041522-094053 · Cited by 11
Liu, L., Hao, X., Bai, Y., & Tian, Y. (2024) · Aging Cell · doi:10.1111/acel.14416 · Cited by 20
“…macromolecules have been recognized for their remarkable bioactivities, such as immunomodulation, anti-cancer properties, antioxidant effects, and cholesterol-lowering capabilities, rendering them promising therapeutic alternatives (Griffin et al., 2021 ; Wheeler et al., 2014 ; Yu et al., 2018 ).”
Kiaheyrati, N., Babaei, A., Ranji, R., Bahadoran, E., Taheri, S., & Farokhpour, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122734 · Cited by 12
Gao, X., & Jiang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359029 · Cited by 12
“Lactobacillus Johnsoni produces the metabolite hypoxanthine, which then binds to inosine receptors, improving the effectiveness of anti-PD-1 therapy against MC38 colon cancer (44).”
BackgroundXue, X., Zhou, H., Gao, J., Li, X., Wang, J., Bai, W., Bai, Y., Fan, L., Chang, H., & Shi, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38339 · Cited by 10
Gut microbiota-derived GlcNAc-MurNAc is a TLR4 agonist that protects the host gut
Li, C., Adamson, C., Ng, A. W. R., Liang, Y., Hong, Z., Loh, J. T., Ng, S.-K., Kwan, J. M. C., Feng, S., Ng, E. W. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60678-5 · Cited by 16
Metadata
- Authors
- Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C.
- Affiliations
- Scripps Research Institute (US)
- Rockefeller University (US)
- Rise Therapeutics, 1405 Research Blvd. Suite 220, Rockville, MD 20850, USA.
- Corresponding author
- Hang, Howard C.
- ORCID
- Venue
- Science
- Published
- 2021-08-27
- Volume
- 373
- Issue
- 6558
- Pages
- 1040-1046
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9503018
- OpenAlex
- W3194929095
- Cited by
- 366
- References
- 75
- Citations by year
- 2026: 69 · 2025: 71 · 2024: 83 · 2023: 80 · 2022: 52 · 2021: 10
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1R01CA245292-01, A1070084)
- Melanoma Research Foundation (Career Development Award)
- ASCRS Research Foundation (HCFR-19-03-02)
- Hope Funds for Cancer Research (HCFR-19-03-02)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- Enterococcus, sagas, peptidoglycan remodeling, cancer immunotherapy, PD-L1 blockade, gut microbiota, muramyl peptides, NOD2 signaling, innate immunity, bacterial cell wall degradation
- MeSH terms
- Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Bacterial Proteins, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, N-Acetylmuramoyl-L-alanine Amidase, Peptide Fragments, Peptidoglycan, Enterococcus faecalis, Signal Transduction, Enterococcus, Enterococcus faecium, Probiotics, Mice, Nod2 Signaling Adaptor Protein, Bacterial Load, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.